Skip to main content
Neurology

SHIELD-DMD to Evaluate Therapeutic Potential of IL-6 Receptor Satralizumab in Duchenne Muscular Dystrophy

The design of a phase 2 trial to investigate the potential of satralizumab in boys with Duchenne muscular dystrophy was recently presented at the 2025 MDA Clinical & Scientific Conference.:

Source: Neurology Read More

Related Posts

Neurology <![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

<![CDATA[Once-Daily Alixorexton Improves Cognition, Fatigue, and Disease Severity in Phase 2 Narcolepsy Type 1 Study]]>

April 21, 2026
Neurology <![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

<![CDATA[NMOSD Associated With Escalation to Rituximab, Elecsys NfL Test Receives European Approval, Neurology by the Numbers]]>

April 20, 2026
Neurology <![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

<![CDATA[GLP-1 Receptor Agonists Show Translational Potential in Alzheimer Disease Despite Mixed Study Results]]>

April 20, 2026